Clinical evidence on PET/CT for radiation therapy planning in prostate cancer

Maria Picchio, Elisabetta Giovannini, Cinzia Crivellaro, Luigi Gianolli, Nadia Di Muzio, Cristina Messa

Research output: Contribution to journalArticlepeer-review


The present chapter is focused on the role of positron emission tomography/computed tomography (PET/CT) and [11C]-labelled Choline ([11C]Choline) for the management of prostate cancer patients for radiation therapy planning. Although still a matter of debate, PET/CT with [11C]Choline is not routinely recommended for selecting patients for prostate cancer primary radiation treatment. However, due to its high accuracy in detecting and localizing recurrences when a biochemical failure occurs, [11C]Choline PET/CT may play a role in the re-staging phase to distinguish patients with local versus distant relapse, thus influencing patient management (curative versus palliative therapy). Limited data are currently available on the role of [11C]Choline PET/CT in target volume selection and delineation. According to available literature, [11C]Choline PET/CT is not clinically recommendable to plan target volume both for primary prostate treatment and for local recurrence. Nevertheless, promising data suggested a potential role of [11C]Choline PET/CT as an image guide tool for the irradiation of prostate cancer relapse.

Original languageEnglish
Pages (from-to)347-350
Number of pages4
JournalRadiotherapy and Oncology
Issue number3
Publication statusPublished - Sep 2010


  • Choline
  • PET
  • Prostate
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology


Dive into the research topics of 'Clinical evidence on PET/CT for radiation therapy planning in prostate cancer'. Together they form a unique fingerprint.

Cite this